US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Castle Biosciences, Inc.

18.50

-0.0400-0.22%

Volume:18.81K

Turnover:347.79K

Market Cap:534.14M

PE:-100.28

High:18.63

Open:18.51

Low:18.31

Close:18.54

Loading ...

Overview Company News Filings

Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review

RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?

GHRS Stock Rallies 55% in a Week: Here's What You Should Know

VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS

Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug

Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss

Simply Wall St.

VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up

CMRX Stock Skyrockets in 3 Months: Here's What You Should Know

FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases

Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet

SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up

FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss

Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CSTL/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSTL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","market":"US","secType":"STK","nameCN":"Castle Biosciences, Inc.","latestPrice":18.5,"timestamp":1750254413063,"preClose":18.54,"halted":0,"volume":18807,"delay":0,"floatShares":26464372,"shares":28872315,"eps":-0.184478,"marketStatus":"Trading","change":-0.04,"latestTime":"06-18 09:46:55 EDT","open":18.51,"high":18.63,"low":18.31,"amount":347792.039637,"amplitude":0.01726,"askPrice":18.64,"askSize":100,"bidPrice":18.48,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-0.184478,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1750276800000},"marketStatusCode":2,"adr":0,"listingDate":1564027200000,"exchange":"NASDAQ","adjPreClose":18.54,"preHourTrading":{"tag":"盘前","latestPrice":18.54,"preClose":18.54,"latestTime":"08:00 EDT","volume":1,"amount":18.54,"timestamp":1750248000927},"postHourTrading":{"tag":"盘后","latestPrice":18.54,"preClose":18.54,"latestTime":"19:14 EDT","volume":10873,"amount":201587.63,"timestamp":1750202069955},"volumeRatio":0.875238,"impliedVol":0.6568,"impliedVolPercentile":0.348},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSTL\",,,,,undefined,":{"symbol":"CSTL","floatShares":26464372,"roa":"-1.79%","roe":"-1.20%","lyrEps":0.656862,"volumeRatio":0.875238,"shares":28872315,"dividePrice":0,"high":18.63,"amplitude":0.01726,"preClose":18.54,"low":18.31,"week52Low":15.45,"pbRate":"1.21","psRate":"1.54","week52High":35.84,"institutionHeld":0,"latestPrice":18.5,"committee":-0.960784,"eps":-0.184478,"divideRate":0,"volume":18807,"delay":0,"ttmEps":-0.184478,"open":18.51,"prevYearClose":26.65,"prevWeekClose":18.75,"prevMonthClose":15.97,"prevQuarterClose":20.02,"fiveDayClose":18.44,"twentyDayClose":16.5,"sixtyDayClose":20.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSTL\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509747047","title":"Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2509747047","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509747047?lang=en_us&edition=fundamental","pubTime":"2025-02-07 21:53","pubTimestamp":1738936380,"startTime":"0","endTime":"0","summary":"Insmed Incorporated INSM announced that the FDA has accepted its new drug application  seeking approval of its reversible inhibitor of dipeptidyl peptidase 1 , brensocatib, for treating patients with non-cystic fibrosis bronchiectasis.With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on Aug. 12, 2025.If approved, brensocatib will become the first and only approved treatment for bronchiectasis, a chronic lung disease with no approved treatments. It would also become the first DPP1 inhibitor to be approved for the treatment of neutrophil-mediated diseases.Last month, the company outlined key pipeline goals for 2025. At the time, management stated that upon approval, it expects to launch brensocatib in the United States in the third quarter of 2025.In the past year, shares of Insmed have skyrocketed 182.7% against the industry’s decline of 6.5%.INSM's Brensocatib NDA Based on Data from ASPEN Study. The latest NDA was based on data from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insmeds-nda-lung-disease-drug-135300938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0889565916.HKD","HRMY","CSTL","LU0053671581.USD","BK4505","LU0320765992.SGD","INSM","ARGX","BK4588","LU0109394709.USD","BK4007","BK4139","BK4196"],"gpt_icon":0},{"id":"2509209101","title":"RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2509209101","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509209101?lang=en_us&edition=fundamental","pubTime":"2025-02-06 23:35","pubTimestamp":1738856100,"startTime":"0","endTime":"0","summary":"Shares of Rezolute RZLT have rallied 30.8% in the past six months against the industry’s decline of 4.1%, driven by investor enthusiasm about the company’s encouraging progress with the development activities for its lead pipeline candidate, ersodetug .Rezolute is a late-stage clinical biotech focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism .The company is evaluating ersodetug in the phase III sunRIZE study for treating patients with congenital HI, an ultra-rare pediatric genetic disorder.An independent Data Monitoring Committee  reviewed the OLA of the sunRIZE study, which evaluated ersodetug in eight infants aged between three months to one year for treating congenital HI. Per the DMC review, treatment with ersodetug was generally safe and well-tolerated in the given patient population. The DMC also approved the enrollment of subsequent infants into the double-blind portion of the study.Some better-ranked stocks in the biotech sector are Harm","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rzlt-shares-rise-30-8-153500425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3B42.SGD","RZLT","BK4566","LU0128526141.USD","BK4196","IE00B7SZLL34.SGD","LU2125154778.USD","IE0002270589.USD","BK4161","LU2360032135.SGD","LU2125154935.USD","BK4007","BMRN","HI","LU0029874061.USD","HRMY","IE00B19Z3581.USD","BK4139","CSTL"],"gpt_icon":0},{"id":"2509209176","title":"GHRS Stock Rallies 55% in a Week: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2509209176","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509209176?lang=en_us&edition=fundamental","pubTime":"2025-02-06 23:25","pubTimestamp":1738855500,"startTime":"0","endTime":"0","summary":"Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the primary goal in a mid-stage study of its investigational, inhalable mebufotenin product candidate, GH001, to treat patients with treatment-resistant depression .Per the data readout from the phase IIb TRD study, 40 patients treated with GH001 achieved a significant 15.2-point reduction in Montgomery-sberg Depression Rating Scale  score by Day 8, while the placebo group, comprising 41 patients, showed a slight increase of 0.3 points. Please note that MADRS is a metric showing the improvement of depressive symptoms in patients compared with placebo after the treatment period.It was observed that most patients receiving GH001 achieved remission with a 57.5% remission rate on Day 8 compared with 0% in the placebo group. Furthermore, in the open-label extension  portion of the phase IIb study, TRD patients who had remission on Day 8 after their first dosage had a 91.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ghrs-stock-rallies-55-week-152500374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","CSTL","GHRS","IE00B19Z3581.USD","IE0002270589.USD","BK4539","BK4566","BMRN","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4548","BK4139","BK4588","ALNY","BK4007","BK4196"],"gpt_icon":0},{"id":"2509127762","title":"VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509127762","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509127762?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:25","pubTimestamp":1738848300,"startTime":"0","endTime":"0","summary":"Viking Therapeutics VKTX reported a fourth-quarter 2024 loss per share of 32 cents, wider than the Zacks Consensus Estimate of a loss of 27 cents. The company had incurred a loss of 25 cents per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it is yet to generate revenues.Research and development expenses surged 51% year over year to $31 million. This uptick was mainly due to increased manufacturing expenses for the company’s drug candidates, along with higher employee-related costs.As of Dec. 31, 2024, Viking Therapeutics had cash, cash equivalents and short-term investments worth $903 million compared with $930 million as of Sept. 30, 2024.VKTX is currently evaluating the potential next steps for VK2809, which completed the phase IIb VOYAGE study last year. Overall data from the study showed that 40-50% of patients who received the drug achiev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vktxs-q4-loss-wider-expected-132500799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSTL","VKTX"],"gpt_icon":1},{"id":"2509466090","title":"PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2509466090","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509466090?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:26","pubTimestamp":1738679160,"startTime":"0","endTime":"0","summary":"PfizerPFE announced positive top-line results from the progression-free survival  analysis of a late-stage study of its oncology drug, Braftovi , for treating patients with metastatic colorectal cancer  harboring a BRAF V600E mutation. Braftovi is an oral small-molecule kinase inhibitor that targetsBRAF V600E.The phase III BREAKWATER study is evaluating the candidate's safety and efficacy in combination with Eli Lilly’s LLY Erbitux  and chemotherapy  in mCRC patients harboring a BRAF V600E mutation.BRAF mutations are found in 8-12% of mCRC cases and are linked to a poorer prognosis. The BRAF V600E mutation is the most common and more than doubles the risk of death compared to patients without any mutation. Despite the high unmet need, no biomarker-driven therapies were approved for previously untreated BRAF V600E-mutant mCRC until December 2024. Thus, Pfizer has the first-mover advantage in t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfes-colorectal-cancer-drug-meets-142600063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BK4W5M84.HKD","LU1093756325.SGD","LU1127390331.HKD","LU2361044865.SGD","LU1623119135.USD","BK4516","LU1720051017.SGD","LU2324357040.USD","LLY","LU0170899867.USD","BK4581","ORR","LU0354030438.USD","LU1023059063.AUD","LU2106854487.HKD","LU1066053197.SGD","LU2361044949.HKD","LU2361045086.USD","BK4007","LU2491049909.HKD","LU0306806265.USD","LU0471298694.HKD","LU1894683264.USD","CSTL","LU0868494617.USD","LU1064131342.USD","LU1291159041.SGD","LU0079474960.USD","IE0002141913.USD","LU1280957306.USD","BK4534","SG9999002232.USD","LU1868836757.USD","IE00B19Z3B42.SGD","ALNY","LU0882574055.USD","LU2237443895.HKD","LU2491050154.USD","PFE","BK4588","LU0640476718.USD","SGXZ99366536.SGD","LU0114720955.EUR","LU0097036916.USD","LU1066051498.USD","PFS","IE00BBT3K403.USD","LU0823416689.USD","LU0238689110.USD","LU2237438978.USD"],"gpt_icon":1},{"id":"2508746140","title":"Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2508746140","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508746140?lang=en_us&edition=fundamental","pubTime":"2025-02-03 22:31","pubTimestamp":1738593060,"startTime":"0","endTime":"0","summary":"BiogenBIIB and Japan-based partner, Eisai, announced an update regarding the regulatory review of an application seeking the approval of Leqembi  for mild cognitive impairment due to Alzheimer’s disease  and mild AD, collectively known as early AD, in the EU.Please note that, in November 2024, the European Medicines Agency’s  Committee for Medicinal Products for Human Use  rendered a positive opinion recommending marketing approval for Leqembi for early AD.Biogen and Eisai announced that the European Commission  has requested the CHMP to reassess new safety data that emerged after the positive opinion and determine if any updates are needed. Additionally, the CHMP will review the clarity of risk minimization measures in its opinion to ensure proper implementation. These discussions are scheduled for an upcoming CHMP meeting later this month.BIIB stock lost 1.6% on Friday following the news. Shares of Biogen have plunged 17.1% in the past three months compared with theindustry’s decline","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-stock-down-regulatory-eu-143100317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0820561818.USD","LU1061106388.HKD","GB00BDT5M118.USD","LU0471298777.SGD","LU0203201768.USD","SG9999014880.SGD","SG9999018865.SGD","BK4139","BK4533","CHMP","LU0061475181.USD","LLY","LU2211815571.USD","LU1720051108.HKD","LU1983299246.USD","BK4201","LU2265009873.SGD","SG9999014898.SGD","PRTA","LU2106854487.HKD","LU2357305700.SGD","LU0943347566.SGD","LU0289739699.SGD","LU1093756325.SGD","IE0009355771.USD","LU0198837287.USD","LU1548497426.USD","BIIB","LU1069344957.HKD","LU1623119135.USD","CSTL","LU0354030438.USD","LU0114720955.EUR","LU0689472784.USD","LU0456855351.SGD","LU1023059063.AUD","LU2361044865.SGD","LU1280957306.USD","LU2491050071.SGD","SG9999014914.USD","LU2237443622.USD","IE00BJT1NW94.SGD","LU2237443382.USD","LU1868836591.USD","LU0466842654.USD","IE00BFTCPJ56.SGD","LU0079474960.USD","EC","LU1366192091.USD"],"gpt_icon":1},{"id":"2508248669","title":"Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2508248669","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508248669?lang=en_us&edition=fundamental","pubTime":"2025-02-01 20:17","pubTimestamp":1738412243,"startTime":"0","endTime":"0","summary":"Many investors define successful investing as beating the market average over the long term. But its virtually certain that sometimes you will buy stocks that fall short of the market average returns. Unfortunately, that's been the case for longer term Castle Biosciences, Inc.  shareholders, since the share price is down 34% in the last three years, falling well short of the market return of around 36%. Furthermore, it's down 15% in about a quarter. That's not much fun for holders.Although the past week has been more reassuring for shareholders, they're still in the red over the last three years, so let's see if the underlying business has been responsible for the decline.Given that Castle Biosciences only made minimal earnings in the last twelve months, we'll focus on revenue to gauge its business development. As a general rule, we think this kind of company is more comparable to loss-making stocks, since the actual profit is so low. For shareholders to have confidence a company will ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strong-week-castle-biosciences-nasdaq-121723277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","USAW.SI","LU2210150020.SGD","USJW.SI","TSYW.SI","IE00B3QW5Z07.USD","QLD","SQQQ","BK4585","NQmain","BK4588","LU2095319765.USD","PSQ","BK4112","LU2210149790.SGD","NVIW.SI","IE00BKPKM429.USD","IE00B64PRP62.GBP",".IXIC","CSTL","MNQmain","TQQQ","IE00BGHQF748.EUR","BK4196","QID"],"gpt_icon":1},{"id":"2508998150","title":"VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2508998150","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508998150?lang=en_us&edition=fundamental","pubTime":"2025-01-31 23:56","pubTimestamp":1738338960,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The pain drug will be marketed by the name of Journavx.Following the nod, Journavx has become the first and only non-opioid oral pain signal inhibitor and the first new class of pain medicine to be approved by the FDA in more than 20 years.Per the company, Journavx has the potential to transform the treatment paradigm of acute pain. Pain is an area with limited treatment options, mostly highly addictive opioid-based medications.Vertex believes Journavx, a non-opioid drug, is an effective and well-tolerated medicine for use in all types of moderate-to-severe acute pain.Shares of VRTX were up more than 8% in after-hours trading on Jan. 30 following the news announcement. The stock was also up in pre-market trading on Jan. 31.Besides acute pain, suzetrigine is also bein","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vrtx-gets-fda-nod-non-155600022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","LU1585245621.USD","LU2362541513.USD","IE00B7SZLL34.SGD","BK4007","LU1430594728.SGD","BK4139","LU1093756168.USD","LU2236285917.USD","IE00B4R5TH58.HKD","LU2362540622.SGD","LU2362541273.HKD","HRMY","VRTX","LU1093756325.SGD","IE0009355771.USD","LU1035775433.USD","LU0109394709.USD","LU1815336091.USD","BK4585","LU0823416689.USD","BK4196","LU0417517546.SGD","IE00B19Z9P08.USD","CSTL","BK4588","LU0289739699.SGD","LU0256863811.USD","LU2462157665.USD","LU2237438978.USD","LU2456880835.USD","VERX","BMRN","LU0234570918.USD","IE00B19Z9Z06.USD","BK4023","BK4533","IE00BJT1NW94.SGD","LU0889565916.HKD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU1069344957.HKD","LU1559883803.SGD","BK4567","IE00B19Z3B42.SGD","IE00B894F039.SGD","LU0061475181.USD","BK4566","LU0757428866.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2508499339","title":"CMRX Stock Skyrockets in 3 Months: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2508499339","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508499339?lang=en_us&edition=fundamental","pubTime":"2025-01-31 23:43","pubTimestamp":1738338180,"startTime":"0","endTime":"0","summary":"Shares of Chimerix CMRX have skyrocketed 323.7% in the past three months following the company’s submission of a new drug application  to the FDA, seeking accelerated approval for its lead candidate, dordaviprone, to treat patients with recurrent H3 K27M-mutant diffuse glioma. CMRX’s dordaviprone is a first-in-class small molecule imipridone with a novel mechanism of action.Chimerix has also requested the FDA to grant the Priority Review status to the dordaviprone NDA filing for the glioma indication. A filing accepted under the regulatory body’s Priority Review pathway reduces the review period to six months from the standard 10 months. This status is given to treatments that the FDA believes, could significantly improve existing options or provide solutions where no approved therapy exists. Subject to a grant from the FDA, a final decision is expected in the third quarter of 2025.Please note that CMRX’s dordaviprone already enjoys the Rare Pediatric Disease Designation for H3 K27M-mu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cmrx-stock-skyrockets-3-months-154300643.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMRN","BK4588","IE0002270589.USD","IE00B19Z3581.USD","BK4139","BK4566","BK4196","IE00B19Z3B42.SGD","BK4548","BK4585","BK4583","CMRX","ALNY","IE00B7SZLL34.SGD","CSTL"],"gpt_icon":0},{"id":"2507487654","title":"FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2507487654","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507487654?lang=en_us&edition=fundamental","pubTime":"2025-01-30 00:34","pubTimestamp":1738168440,"startTime":"0","endTime":"0","summary":"Allogene Therapeutics, Inc. ALLO announced that the FDA has cleared its investigational new drug  application to begin clinical studies on its investigational CRISPR-based allogenic CAR-T therapy, ALLO-329, for the treatment of various autoimmune diseases.The phase I RESOLUTION basket study will evaluate the safety and preliminary efficacy of ALLO-329 in patients with systemic lupus erythematosus, including lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis.The study, which aims to offer a key understanding of ALLO-329's potential to transform the treatment paradigm across a range of autoimmune diseases, is expected to begin in mid-2025. The company expects to have proof-of-concept from the basket study by the end of 2025.A next-generation allogeneic CAR T-cell therapy, ALLO-329, works by targeting both CD19+ B-cells and CD70+ activated T-cells. Additionally, the candidate incorporates ALLO’s proprietary Dagger technology, which is designed to reduce or eliminat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-clears-allogenes-ind-car-163400440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HRMY","BK4566","BMRN","BK4007","IE00B19Z3B42.SGD","CSTL","ALLO","BK4505","IE00B19Z3581.USD","BK4196","IE0002270589.USD","CAR","BK4139","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2507655586","title":"Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2507655586","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507655586?lang=en_us&edition=fundamental","pubTime":"2025-01-29 22:55","pubTimestamp":1738162505,"startTime":"0","endTime":"0","summary":"Shares of Castle Biosciences, Inc.  have gained 1.5% over the past four weeks to close the last trading session at $27.06, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $41 indicates a potential upside of 51.5%.However, an impressive consensus price target is not the only factor that indicates a potential upside in CSTL. This view is strengthened by the agreement among analysts that the company will report better earnings than what they estimated earlier. Though a positive trend in earnings estimate revisions doesn't give any idea as to how much the stock could surge, it has proven effective in predicting an upside.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-think-castle-145505452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","CSTL"],"gpt_icon":0},{"id":"2507542821","title":"SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2507542821","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507542821?lang=en_us&edition=fundamental","pubTime":"2025-01-29 00:54","pubTimestamp":1738083240,"startTime":"0","endTime":"0","summary":"Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE.Per Sage Therapeutics, the BIIB offer significantly undervalues the company and is not in the best interest of shareholders.SAGE’s board of directors has now started exploring strategic alternatives and evaluating other options to maximize its shareholders’ value.Shares of SAGE were up 4.8% on Jan. 27 following the news announcement.In the past year, the stock has plunged 72% compared with the industry’s decline of 12.4%.Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price represented a premium of 30% on Sage Therapeutics’ closing price of $5.55 on Jan. 10.Biogen currently owns a 10.2% stake in SAGE, per a SEC filing by the company.Some better-ranked stocks in the biotech sector are Harmony Biosciences ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-rejects-biogens-offer-buy-165400180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4561","MCI","IE00B894F039.SGD","BIIB","BK4585","BK4588","IE00B19Z9Z06.USD","ET","BK4533","SAGE","BK4144","LU0320765992.SGD","IE00B19Z9P08.USD","LU0109394709.USD","HRMY","LU0234570918.USD","LU0889565916.HKD","BK4196","PPD","BK4581","BK4007","BK4532","CSTL","BK4530","BK4121","BK4590"],"gpt_icon":0},{"id":"2507611549","title":"FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=2507611549","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507611549?lang=en_us&edition=fundamental","pubTime":"2025-01-29 00:11","pubTimestamp":1738080660,"startTime":"0","endTime":"0","summary":"AstraZenecaAZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application  seeking approval for expanded use of Enhertu  for HER2-low metastatic breast cancer in the United States. The approval of the added indication has triggered a $175 million milestone payment from AstraZeneca to Daiichi Sankyo.The companies’ sBLA was seeking approval for Enhertu to treat unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer in adult patients who have received at least one endocrine therapy in the metastatic setting.The nod in the United States expands the approved indication of Enhertu in HER2-low metastatic breast cancer to include use in an earlier disease setting as well as in a broader patient population that includes HER2-ultralow. The drug has earlier received the FDA’s Breakthrough Therapy designation in the United States for this new indication.In three months, shares of AstraZeneca have lost 6.8% compared with th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-expands-label-azns-enhertu-161100900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","CSTL","BK4548","BMRN","BK4007","LU1829250122.USD","BK4568","BK4588","BK4566","IE00B7SZLL34.SGD","LU0320765992.SGD","BK4080","BK4139","DSKYF","LU2462157665.USD","BK4196","LU2417539215.USD","LU2456880835.USD","ALNY","BK4211","LU0109394709.USD","IE00B19Z3581.USD","LU2236285917.USD","PFS","BK4585","DSNKY","IE0002270589.USD","BK4231","IE00B19Z3B42.SGD","BK4195","ADC","AZN"],"gpt_icon":0},{"id":"2507543472","title":"PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor","url":"https://stock-news.laohu8.com/highlight/detail?id=2507543472","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507543472?lang=en_us&edition=fundamental","pubTime":"2025-01-28 23:22","pubTimestamp":1738077720,"startTime":"0","endTime":"0","summary":"Shares of Pfizer PFE rose nearly 3% on Monday following a report issued by Bloomberg, which stated that activist investor Starboard did not nominate any director to Pfizer’s board ahead of Jan. 25.With the expiry of the deadline, Starboard has foregone an opportunity to bring changes in PFE’s board. This signals a less confrontational approach, at least for this year. Shareholders are set to convene at Pfizer’s annual meeting in April to vote on director seats for the year.The article, however, pointed out that Starboard could still try to make the changes in Pfizer’s board next year if the two parties are unable to reach an agreement.Bloomberg claims to have contacted both Pfizer and Starboard, who have either declined to comment on the above news or are yet to respond.The above article provides some respite to Pfizer’s management, which was accused last year by Starboard of making poor capital allocation, research and development (R&D) failures and problems with forecasting and budge","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfe-stock-rises-reports-averting-152200714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1894683264.USD","BK4568","BK4139","BK4599","BK4534","LU0321505868.SGD","LU0289739699.SGD","SG9999002232.USD","LU0985481810.HKD","SG9999001176.USD","BK4533","ERAS","LU0225771236.USD","BK4007","IE0002270589.USD","LU0225284248.USD","SG9999011175.SGD","CTMX","LU0058720904.USD","SGXZ57979304.SGD","SG9999002224.SGD","SG9999001176.SGD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU1023059063.AUD","CSTL","LU0170899867.USD","LU0456855351.SGD","IE00BBT3K403.USD","IE00BLSP4452.SGD","LU1883839398.USD","BK4588","BK4585","LU1066053197.SGD","LU0234572021.USD","LU0306807586.USD","IE000M9KFDE8.USD","IE00BLSP4239.USD","LU1894683348.USD","BK4550","LU0122379950.USD","BK4539","LU1066051498.USD","IE00B19Z3581.USD","PFE","LU0868494617.USD","LU1057294990.SGD","BK4196","BK4592","SG9999013999.USD"],"gpt_icon":0},{"id":"2506304692","title":"NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2506304692","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506304692?lang=en_us&edition=fundamental","pubTime":"2025-01-27 22:52","pubTimestamp":1737989520,"startTime":"0","endTime":"0","summary":"Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage study of its investigational candidate, amycretin, in 125 overweight/obese patients. Amycretin is NVO’s unimolecular GLP-1 and amylin receptor agonist intended for once-weekly subcutaneous administration.The phase Ib/IIa study evaluated the safety, tolerability, pharmacokinetics and proof-of-conceptof three doses of amycretin in obesity patients for a total treatment duration of up to 36 weeks.Per Novo Nordisk, the study's primary safety endpoint was met as amycretin demonstrated a safety profileconsistent with incretin-based therapies. Treatment-related adverse events were mostly mild to moderate in severity.NVO shares have plunged 21.7% in the past three months compared with the industry’s 12.2% decline.Detailed Results From the Obesity Study of NVO’s Amycretin. Some better-ranked stocks from the sector areCastle BiosciencesCSTL, BioMarin Pharmaceutical BMRN ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-stock-rises-obesity-drug-145200349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMRN","LU1093756325.SGD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","BK4585","BK4196","BK4139","LU0154236417.USD","IE00B19Z3581.USD","BK4588","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","BK4532","ALNY","BK4599","BK4566","CSTL","IE0002270589.USD","BK4548","BK4007","LU1093756168.USD","NVO"],"gpt_icon":1},{"id":"2506893089","title":"Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2506893089","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506893089?lang=en_us&edition=fundamental","pubTime":"2025-01-24 23:56","pubTimestamp":1737734160,"startTime":"0","endTime":"0","summary":"Shares of Anavex Life Sciences AVXL, a clinical-stage biotech making medicines to treat central nervous system  diseases, have skyrocketed 94.7% in the past three months due to recent pipeline successes.Anavex Life Sciences’ clinical developmental pipeline includes two candidates, ANAVEX 2-73  and ANAVEX 3-71. Both these candidates are being developed in separate studies across various stages of development to treat a plethora of CNS indications like Alzheimer’s disease , Parkinson’s disease and schizophrenia, among others.AVXL shares have rallied 53.6% in the past year against the industry’s 12.4% decline.Upbeat Initial Data From AVXL’s Schizophrenia Study. In October 2024, Anavex Life Sciences reported positive initial biomarker results from Part A of an ongoing mid-stage study of ANAVEX 3-71 for schizophrenia. This multiple ascending dose portion of the phase II ANAVEX 3-71-SZ-001 study, evaluated two oral, daily doses of the candidate  in 16 patients for 10 days.The MAA submission ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anavex-life-sciences-stock-skyrockets-155600615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4215","IE00B19Z3581.USD","BK4548","IE00B7SZLL34.SGD","BK4588","BK4139","ALNY","BK4566","BMRN","BK4135","BK4196","IE0002270589.USD","IE00B19Z3B42.SGD","MAA","CSTL","BK4585","AVXL","CNS"],"gpt_icon":0},{"id":"2506893707","title":"Is it a Good Idea to Invest in Beam Therapeutics Stock Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2506893707","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506893707?lang=en_us&edition=fundamental","pubTime":"2025-01-24 23:40","pubTimestamp":1737733200,"startTime":"0","endTime":"0","summary":"Beam Therapeutics BEAM is developing its lead pipeline candidate, BEAM-101, a base-editing therapy, in the phase I/II BEACON study for treating sickle cell disease , an inherited blood disorder.BEAM’s pipeline of gene editing therapies is based on its proprietary base editing technology.The company believes that its innovative next-generation technology called base-editing technology can provide a superior way to modify genes and could open up entirely new applications in gene editing, targeting a wide range of severe diseases. It can also make more precise single-base changes at specific locations in genes, resulting in predictable edits in all cells, without needing to damage or make double-stranded breaks in the DNA.Beam Therapeutics currently has a Zacks Rank #2 . In the past 60 days, estimates for BEAM’s 2025 loss per share have narrowed from $4.62 to $4.32.In the past 60 days, estimates for Voyager Therapeutics’ loss per share have narrowed from $1.72 to $1.58 for 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/good-idea-invest-beam-therapeutics-154000464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4556","CSTL","BK4139","BK4535","LENZ","BK4505","BK4585","BK4007","HRMY","SCD","VYGR","BK4196","BEAM","BK4588"],"gpt_icon":0},{"id":"2505044214","title":"CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2505044214","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505044214?lang=en_us&edition=fundamental","pubTime":"2025-01-24 00:19","pubTimestamp":1737649140,"startTime":"0","endTime":"0","summary":"Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 , a cardiac myosin inhibitor, for treating heart failure patients. The intended patient population includes those with symptomatic heart failure with preserved ejection fraction  with left ventricular ejection fraction  ≥60%.Cytokinetics plans to enroll approximately 60 HFpEF patients in the phase II AMBER-HFpEF study who will receive CK-586 or placebo in three dose escalation cohorts. In the past three months, CYTK shares have lost 10.6% compared with the industry’s 8.7% decline.Cytokinetics is developing its lead investigational candidate, aficamten, a novel, oral and small-molecule cardiac myosin inhibitor, to reduce the hypercontractility associated withhypertrophic cardiomyopathy . A regulatory filing for aficamten to treat obstructive HCM is currently under review by the FDA. A final decision from the regulatory body is expected on Sept. 26, 2025. T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytk-stock-rises-enrollment-begins-161900028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4531","BK4007","CTMX","BK4196","IE0002270589.USD","IE00B19Z3B42.SGD","BK4588","BK4505","HCM","IE00B7SZLL34.SGD","BK4566","CYTK","BK4585","IE00B19Z3581.USD","CSTL","BK4139","BMRN"],"gpt_icon":0},{"id":"2505489620","title":"Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2505489620","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505489620?lang=en_us&edition=fundamental","pubTime":"2025-01-23 22:13","pubTimestamp":1737641580,"startTime":"0","endTime":"0","summary":"Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company’s voluntary decision to halt dosing in the ongoing mid-stage study of its pipeline candidate, cibotercept , to treat patients with pulmonary arterial hypertension , a kind of lung disease.Keros Therapeutics’ decision was based on unexpected adverse pericardial effusion events that were observed during the study's safety review by an independent data monitoring committee . Cibotercept is an investigational modified ActRIIB fusion protein.The phase II TROPOSstudy is evaluating three doses of cibotercept  in combination with background therapy to treat PAH patients. After consulting with the DMC, Keros Therapeutics initially chose to suspend dosing in the 3 mg/kg and 4.5 mg/kg treatment arms of the TROPOS study while continuing dosing in the 1.5 mg/kg arm. However, earlier this month, the company announced the suspension of dosing i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keros-therapeutics-stock-plunges-81-141300812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMRN","IE0002270589.USD","IE00B19Z3581.USD","BK4139","BK4566","BK4196","CTMX","IE00B19Z3B42.SGD","KROS","LENZ","IE00B7SZLL34.SGD","CSTL"],"gpt_icon":0},{"id":"2505017911","title":"NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2505017911","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505017911?lang=en_us&edition=fundamental","pubTime":"2025-01-23 21:56","pubTimestamp":1737640560,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics NTLA announced that it has dosed the first patient in the phase III HAELO study evaluating NTLA-2002, its novel in vivo CRISPRgene editing therapy for the treatment of hereditary angioedema .Shares of the company were up 10.8% on Jan. 22 following the announcement of the news.The global double-blind, placebo-controlled HAELO study will evaluate the safety and efficacy of NTLA-2002 in adults with Type I or Type II HAE. The key endpoint of the study is to see the change in the number of HAE attacks from week five through week 28 of treatment.Enrollment of patients in the study is expected to be completed in the second half of 2025. Intellia plans to submit a biologics license application for NTLA-2002 in HAE in 2026. Upon potential approval, the company plans to launch NTLA-2002 in 2027 in the United States.Despite the current treatment options that require chronic administration for disease control, HAE attacks still occur. NTLA-2002 aims to prevent HAE attacks by ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ntla-begins-dosing-pivotal-study-135600627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0205193047.USD","LU0320765992.SGD","BK4588","BK4556","LU0889565916.HKD","LU1169589451.USD","LU2362541273.HKD","VYGR","LU2362541513.USD","LU0114720955.EUR","BK4585","HAE","LU0289739699.SGD","IE00BLDYK493.USD","LU2023250504.SGD","LU2468319806.SGD","LU2237438978.USD","LU1169590202.USD","LU2362540622.SGD","LU0106261612.USD","LU1861558580.USD","BK4535","LU0058720904.USD","LU0012050646.USD","NTLA","BK4198","LU0053666078.USD","CSTL","LU0823416689.USD","REGN","BK4139","LU0882574055.USD","LU0109394709.USD","LU2106854487.HKD","LU2089984988.USD","LU1861559042.SGD","LU1974910355.USD","LU1917777945.USD","LU0205194284.USD","IE00B64QTZ34.USD","BK4196"],"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":4,"totalSize":143,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSTL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-05","symbol":"CSTL","fiscalQuarterEnding":"2025/03","expectedEps":-0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746417600000,"reportTimeType":"post","actualEps":-0.2},{"market":"US","date":"2025-02-27","symbol":"CSTL","fiscalQuarterEnding":"2024/12","expectedEps":0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":0.32},{"market":"US","date":"2025-01-12","symbol":"CSTL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736658000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-04","symbol":"CSTL","fiscalQuarterEnding":"2024/09","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730696400000,"reportTimeType":"post","actualEps":0.08},{"market":"US","date":"2024-08-05","symbol":"CSTL","fiscalQuarterEnding":"2024/06","expectedEps":-0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1722830400000,"reportTimeType":"post","actualEps":0.31}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSTL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSTL\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5556,"buy":0.4444,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5556,"analysts":9,"updateTime":1702526400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSTL\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSTL","date":"2025-06-17","current":-109.759225,"percent":0.183442,"low":-703.916349,"twenty":-97.732254,"median":-12.899374,"eighty":-4.847918,"high":155.734424,"avg":-50.599424,"sd":147.336455,"marketCap":556369510},"quantilePoints":[{"date":"2020-06-19","current":101.300632,"twenty":-137.181173,"median":72.096597,"eighty":89.912228,"marketCap":729871056},{"date":"2020-06-26","current":93.605957,"twenty":-130.766504,"median":72.216999,"eighty":90.734693,"marketCap":674430922},{"date":"2020-07-02","current":102.622433,"twenty":-129.220801,"median":72.241079,"eighty":91.444186,"marketCap":739394631},{"date":"2020-07-10","current":111.372149,"twenty":-123.084358,"median":72.843088,"eighty":91.857697,"marketCap":802436336},{"date":"2020-07-17","current":117.305694,"twenty":-115.1504,"median":73.469177,"eighty":92.281742,"marketCap":845187527},{"date":"2020-07-24","current":106.527432,"twenty":-106.40243,"median":74.167508,"eighty":92.916333,"marketCap":767530147},{"date":"2020-07-31","current":105.654256,"twenty":-102.767312,"median":74.396271,"eighty":93.757226,"marketCap":761238917},{"date":"2020-08-07","current":114.058572,"twenty":-101.783309,"median":74.456472,"eighty":94.202941,"marketCap":821792012},{"date":"2020-08-14","current":114.576879,"twenty":-98.400291,"median":74.981827,"eighty":94.738911,"marketCap":813266685},{"date":"2020-08-21","current":126.944083,"twenty":-97.554536,"median":75.780892,"eighty":96.467657,"marketCap":901049101},{"date":"2020-08-28","current":126.334042,"twenty":-95.952482,"median":76.635745,"eighty":97.420065,"marketCap":896719027},{"date":"2020-09-04","current":133.238602,"twenty":-93.309499,"median":76.98491,"eighty":99.303027,"marketCap":945727595},{"date":"2020-09-11","current":134.763705,"twenty":-92.601993,"median":77.514678,"eighty":100.272889,"marketCap":956552781},{"date":"2020-09-18","current":141.52962,"twenty":-91.068613,"median":78.020365,"eighty":102.449512,"marketCap":1004577242},{"date":"2020-09-25","current":137.592079,"twenty":-89.595469,"median":78.419535,"eighty":103.419182,"marketCap":976628580},{"date":"2020-10-02","current":142.611057,"twenty":-88.909949,"median":79.699487,"eighty":106.169125,"marketCap":1012253283},{"date":"2020-10-09","current":152.122158,"twenty":-87.950343,"median":80.235758,"eighty":108.912247,"marketCap":1079763078},{"date":"2020-10-16","current":138.5626,"twenty":-87.36482,"median":81.186932,"eighty":110.294181,"marketCap":983517335},{"date":"2020-10-23","current":143.747953,"twenty":-87.250969,"median":82.192491,"eighty":112.350606,"marketCap":1020322967},{"date":"2020-10-30","current":128.746478,"twenty":-87.169646,"median":82.764196,"eighty":114.265895,"marketCap":913842503},{"date":"2020-11-06","current":143.359744,"twenty":-86.063659,"median":84.023258,"eighty":116.079799,"marketCap":1017567465},{"date":"2020-11-13","current":-300.218351,"twenty":-87.950343,"median":82.764196,"eighty":115.530762,"marketCap":1002729291},{"date":"2020-11-20","current":-286.626257,"twenty":-92.601993,"median":82.192491,"eighty":115.132049,"marketCap":957331698},{"date":"2020-11-27","current":-265.105442,"twenty":-97.570801,"median":81.439776,"eighty":114.888032,"marketCap":885452175},{"date":"2020-12-04","current":-309.99512,"twenty":-109.964358,"median":80.259839,"eighty":114.369556,"marketCap":1035383700},{"date":"2020-12-11","current":-356.136701,"twenty":-134.615305,"median":79.885626,"eighty":113.96642,"marketCap":1189496581},{"date":"2020-12-18","current":-450.787075,"twenty":-141.029974,"median":78.954401,"eighty":113.756623,"marketCap":1505628832},{"date":"2020-12-24","current":-515.732815,"twenty":-143.704042,"median":78.164847,"eighty":113.491008,"marketCap":1722547602},{"date":"2020-12-31","current":-485.646593,"twenty":-146.146252,"median":77.835827,"eighty":112.857956,"marketCap":1622059619},{"date":"2021-01-08","current":-575.760614,"twenty":-151.556214,"median":77.346115,"eighty":112.012372,"marketCap":1923040451},{"date":"2021-01-15","current":-536.200125,"twenty":-153.642914,"median":76.720026,"eighty":111.384472,"marketCap":1790908417},{"date":"2021-01-22","current":-572.578418,"twenty":-155.265902,"median":76.491263,"eighty":111.374614,"marketCap":1912411915},{"date":"2021-01-29","current":-483.332268,"twenty":-167.600615,"median":75.585094,"eighty":110.83863,"marketCap":1614329774},{"date":"2021-02-05","current":-671.081866,"twenty":-169.640943,"median":74.685236,"eighty":110.157158,"marketCap":2241413434},{"date":"2021-02-12","current":-690.970595,"twenty":-171.341217,"median":74.456472,"eighty":109.561717,"marketCap":2307841788},{"date":"2021-02-19","current":-656.255723,"twenty":-173.845257,"median":74.33607,"eighty":109.348881,"marketCap":2191894116},{"date":"2021-02-26","current":-550.230719,"twenty":-178.868792,"median":74.167508,"eighty":109.144161,"marketCap":1837770601},{"date":"2021-03-05","current":-498.881637,"twenty":-200.184042,"median":73.01165,"eighty":108.912247,"marketCap":1666264669},{"date":"2021-03-12","current":-155.908697,"twenty":-197.741831,"median":72.590244,"eighty":108.442961,"marketCap":1603365036},{"date":"2021-03-19","current":-161.592235,"twenty":-187.710216,"median":72.241079,"eighty":107.618901,"marketCap":1661814548},{"date":"2021-03-26","current":-145.658896,"twenty":-181.094605,"median":72.144757,"eighty":106.811214,"marketCap":1497956087},{"date":"2021-04-01","current":-172.643561,"twenty":-179.425246,"median":72.072517,"eighty":106.28856,"marketCap":1775466377},{"date":"2021-04-09","current":-168.830246,"twenty":-179.507526,"median":71.807633,"eighty":105.852599,"marketCap":1736250252},{"date":"2021-04-16","current":-159.114795,"twenty":-178.054894,"median":70.96482,"eighty":105.703373,"marketCap":1636336556},{"date":"2021-04-23","current":-164.142541,"twenty":-177.570402,"median":70.844418,"eighty":105.135102,"marketCap":1688041893},{"date":"2021-04-30","current":-168.180083,"twenty":-176.766636,"median":70.627694,"eighty":103.731578,"marketCap":1729563976},{"date":"2021-05-07","current":-146.959621,"twenty":-175.143647,"median":69.495918,"eighty":102.75377,"marketCap":1511332740},{"date":"2021-05-14","current":-91.341496,"twenty":-173.860714,"median":69.134713,"eighty":102.6761,"marketCap":1382362194},{"date":"2021-05-21","current":-95.480588,"twenty":-173.49996,"median":68.484543,"eighty":102.639567,"marketCap":1445003222},{"date":"2021-05-28","current":-99.222328,"twenty":-172.874456,"median":67.172163,"eighty":102.507152,"marketCap":1501630711},{"date":"2021-06-04","current":-104.801825,"twenty":-172.506749,"median":65.944065,"eighty":102.127511,"marketCap":1586070816},{"date":"2021-06-11","current":-119.023747,"twenty":-171.940864,"median":65.462458,"eighty":101.207424,"marketCap":1801305386},{"date":"2021-06-18","current":-121.623097,"twenty":-171.761303,"median":65.089212,"eighty":100.776014,"marketCap":1840643952},{"date":"2021-06-25","current":-121.490646,"twenty":-171.341217,"median":64.848409,"eighty":100.452102,"marketCap":1838639439},{"date":"2021-07-02","current":-117.450892,"twenty":-171.339369,"median":64.547404,"eighty":99.99422,"marketCap":1777501796},{"date":"2021-07-09","current":-121.507203,"twenty":-171.331975,"median":62.921979,"eighty":99.596394,"marketCap":1838890003},{"date":"2021-07-16","current":-107.599851,"twenty":-170.645651,"median":-30.05226,"eighty":99.432751,"marketCap":1628416150},{"date":"2021-07-23","current":-113.907828,"twenty":-170.627605,"median":-66.775802,"eighty":99.270596,"marketCap":1723881076},{"date":"2021-07-30","current":-115.646247,"twenty":-170.259225,"median":-79.533458,"eighty":98.781094,"marketCap":1750190308},{"date":"2021-08-06","current":-118.907852,"twenty":-170.259225,"median":-80.976934,"eighty":98.358362,"marketCap":1799551438},{"date":"2021-08-13","current":-71.922702,"twenty":-169.486373,"median":-79.89941,"eighty":97.576447,"marketCap":1621785000},{"date":"2021-08-20","current":-73.898232,"twenty":-168.830246,"median":-78.110313,"eighty":97.380969,"marketCap":1666331236},{"date":"2021-08-27","current":-82.916473,"twenty":-168.790806,"median":-79.533458,"eighty":97.12033,"marketCap":1869683545},{"date":"2021-09-03","current":-85.70677,"twenty":-168.558951,"median":-80.554542,"eighty":96.729373,"marketCap":1932601958},{"date":"2021-09-10","current":-83.128535,"twenty":-168.255857,"median":-81.000595,"eighty":96.620807,"marketCap":1874465345},{"date":"2021-09-17","current":-86.298313,"twenty":-167.864896,"median":-81.677581,"eighty":96.467657,"marketCap":1945940661},{"date":"2021-09-24","current":-80.851653,"twenty":-167.600615,"median":-81.817096,"eighty":96.094956,"marketCap":1823123920},{"date":"2021-10-01","current":-72.927209,"twenty":-167.548158,"median":-81.052554,"eighty":95.725323,"marketCap":1644435629},{"date":"2021-10-08","current":-68.418088,"twenty":-166.747019,"median":-80.939604,"eighty":95.341474,"marketCap":1542759474},{"date":"2021-10-15","current":-70.962839,"twenty":-166.488822,"median":-80.193143,"eighty":94.738911,"marketCap":1600141066},{"date":"2021-10-22","current":-70.014138,"twenty":-166.318802,"median":-79.455917,"eighty":94.477414,"marketCap":1578748806},{"date":"2021-10-29","current":-69.590013,"twenty":-165.92895,"median":-79.054701,"eighty":94.395866,"marketCap":1569185207},{"date":"2021-11-05","current":-66.46488,"twenty":-165.628697,"median":-75.845859,"eighty":94.279373,"marketCap":1498716585},{"date":"2021-11-12","current":-43.948833,"twenty":-165.400692,"median":-74.221907,"eighty":94.202941,"marketCap":1307521726},{"date":"2021-11-19","current":-40.394148,"twenty":-165.136289,"median":-73.228561,"eighty":94.032207,"marketCap":1201766292},{"date":"2021-11-26","current":-36.669382,"twenty":-164.802892,"median":-72.66492,"eighty":93.911867,"marketCap":1090950790},{"date":"2021-12-03","current":-35.232201,"twenty":-164.332488,"median":-72.525406,"eighty":93.857997,"marketCap":1048193210},{"date":"2021-12-10","current":-35.043363,"twenty":-164.069675,"median":-71.699478,"eighty":93.782419,"marketCap":1042575102},{"date":"2021-12-17","current":-36.565484,"twenty":-163.125113,"median":-70.962839,"eighty":93.656387,"marketCap":1087859706},{"date":"2021-12-23","current":-36.824936,"twenty":-162.260438,"median":-70.538714,"eighty":93.390391,"marketCap":1095578673},{"date":"2021-12-31","current":-37.07574,"twenty":-161.75254,"median":-70.326651,"eighty":93.033305,"marketCap":1103040341},{"date":"2022-01-07","current":-33.80664,"twenty":-160.853861,"median":-70.081106,"eighty":92.949516,"marketCap":1005781361},{"date":"2022-01-14","current":-31.297701,"twenty":-159.513129,"median":-69.768592,"eighty":92.804142,"marketCap":931137898},{"date":"2022-01-21","current":-28.661836,"twenty":-159.163373,"median":-69.221694,"eighty":92.613304,"marketCap":852718272},{"date":"2022-01-28","current":-32.764914,"twenty":-159.153657,"median":-68.462733,"eighty":92.417037,"marketCap":974788953},{"date":"2022-02-04","current":-36.620613,"twenty":-159.037071,"median":-68.077672,"eighty":92.363653,"marketCap":1089499863},{"date":"2022-02-11","current":-37.07272,"twenty":-158.52701,"median":-67.458226,"eighty":92.230539,"marketCap":1102950479},{"date":"2022-02-18","current":-33.933566,"twenty":-157.725045,"median":-66.676942,"eighty":92.12856,"marketCap":1009557525},{"date":"2022-02-25","current":-38.121947,"twenty":-157.70385,"median":-56.620469,"eighty":92.103044,"marketCap":1134166058},{"date":"2022-03-04","current":-34.317143,"twenty":-156.502465,"median":-46.976268,"eighty":91.895938,"marketCap":1073852040},{"date":"2022-03-11","current":-32.441312,"twenty":-155.908697,"median":-44.969316,"eighty":91.848137,"marketCap":1015153549},{"date":"2022-03-18","current":-36.6396,"twenty":-155.213239,"median":-44.561123,"eighty":91.680837,"marketCap":1146526362},{"date":"2022-03-25","current":-34.406468,"twenty":-154.956761,"median":-41.163763,"eighty":91.549188,"marketCap":1076647206},{"date":"2022-04-01","current":-37.337961,"twenty":-153.952054,"median":-39.575131,"eighty":91.549188,"marketCap":1168379479},{"date":"2022-04-08","current":-26.594568,"twenty":-153.917029,"median":-38.48489,"eighty":91.417935,"marketCap":832197215},{"date":"2022-04-14","current":-21.064522,"twenty":-153.883221,"median":-38.135515,"eighty":91.392618,"marketCap":659151015},{"date":"2022-04-22","current":-18.65924,"twenty":-153.705343,"median":-38.019584,"eighty":91.277765,"marketCap":583884947},{"date":"2022-04-29","current":-18.194999,"twenty":-153.646928,"median":-37.870138,"eighty":90.837881,"marketCap":569357910},{"date":"2022-05-06","current":-17.742098,"twenty":-153.581085,"median":-37.62719,"eighty":90.669444,"marketCap":555185744},{"date":"2022-05-13","current":-10.02426,"twenty":-153.127806,"median":-37.342022,"eighty":90.431678,"marketCap":517602654},{"date":"2022-05-20","current":-11.01092,"twenty":-152.745149,"median":-37.268917,"eighty":90.138886,"marketCap":568548831},{"date":"2022-05-27","current":-11.534765,"twenty":-152.15131,"median":-37.07423,"eighty":89.945688,"marketCap":595597574},{"date":"2022-06-03","current":-9.714021,"twenty":-151.992333,"median":-36.988631,"eighty":89.740147,"marketCap":501583495},{"date":"2022-06-10","current":-9.890877,"twenty":-151.80124,"median":-36.824936,"eighty":89.553726,"marketCap":510715451},{"date":"2022-06-17","current":-8.14483,"twenty":-151.608171,"median":-36.696416,"eighty":89.491586,"marketCap":420558272},{"date":"2022-06-24","current":-12.130705,"twenty":-151.344402,"median":-36.658551,"eighty":89.461816,"marketCap":626368976},{"date":"2022-07-01","current":-11.458757,"twenty":-150.793512,"median":-36.620613,"eighty":89.366342,"marketCap":591672918},{"date":"2022-07-08","current":-13.133538,"twenty":-150.278593,"median":-36.428467,"eighty":89.249147,"marketCap":678150213},{"date":"2022-07-15","current":-12.588852,"twenty":-149.603714,"median":-36.089951,"eighty":89.1582,"marketCap":650025379},{"date":"2022-07-22","current":-12.950279,"twenty":-149.104402,"median":-35.730106,"eighty":89.071615,"marketCap":668687652},{"date":"2022-07-29","current":-14.23309,"twenty":-147.282584,"median":-35.640177,"eighty":88.843853,"marketCap":734925580},{"date":"2022-08-05","current":-15.556624,"twenty":-147.050863,"median":-35.579565,"eighty":88.468661,"marketCap":803266299},{"date":"2022-08-12","current":-20.060215,"twenty":-146.936061,"median":-35.460837,"eighty":88.420861,"marketCap":892519093},{"date":"2022-08-19","current":-18.842653,"twenty":-146.702706,"median":-35.366658,"eighty":88.334821,"marketCap":838347339},{"date":"2022-08-26","current":-18.287067,"twenty":-146.099345,"median":-35.166981,"eighty":87.890279,"marketCap":813628189},{"date":"2022-09-02","current":-16.543472,"twenty":-145.861154,"median":-35.147161,"eighty":86.833894,"marketCap":736052134},{"date":"2022-09-09","current":-17.335478,"twenty":-145.658896,"median":-35.015504,"eighty":86.661813,"marketCap":771290071},{"date":"2022-09-16","current":-16.04699,"twenty":-144.832405,"median":-34.913637,"eighty":86.238683,"marketCap":713962681},{"date":"2022-09-23","current":-14.569367,"twenty":-144.059553,"median":-34.541755,"eighty":85.557518,"marketCap":648220261},{"date":"2022-09-30","current":-15.414567,"twenty":-143.904983,"median":-34.361806,"eighty":85.203906,"marketCap":685824925},{"date":"2022-10-07","current":-15.733734,"twenty":-143.10859,"median":-34.256358,"eighty":84.606403,"marketCap":700025288},{"date":"2022-10-14","current":-13.014907,"twenty":-142.900276,"median":-33.942644,"eighty":84.37758,"marketCap":579059235},{"date":"2022-10-21","current":-12.701651,"twenty":-142.591135,"median":-33.780695,"eighty":84.023258,"marketCap":565121842},{"date":"2022-10-28","current":-13.848286,"twenty":-141.740998,"median":-33.572754,"eighty":83.567141,"marketCap":616137960},{"date":"2022-11-04","current":-10.918859,"twenty":-139.963439,"median":-33.417462,"eighty":82.764196,"marketCap":578153577},{"date":"2022-11-11","current":-11.152763,"twenty":-139.808869,"median":-32.603113,"eighty":82.764196,"marketCap":590538818},{"date":"2022-11-18","current":-10.45105,"twenty":-139.422443,"median":-31.297701,"eighty":82.306669,"marketCap":553383096},{"date":"2022-11-25","current":-10.585421,"twenty":-137.629427,"median":-30.939428,"eighty":82.215327,"marketCap":560498021},{"date":"2022-12-02","current":-12.795071,"twenty":-137.051739,"median":-30.146712,"eighty":81.917812,"marketCap":677499018},{"date":"2022-12-09","current":-11.107973,"twenty":-132.017079,"median":-29.830488,"eighty":81.521649,"marketCap":588167176},{"date":"2022-12-16","current":-11.978894,"twenty":-129.220801,"median":-29.148408,"eighty":81.035226,"marketCap":634282434},{"date":"2022-12-23","current":-11.560852,"twenty":-127.462725,"median":-28.661836,"eighty":80.413953,"marketCap":612147110},{"date":"2022-12-30","current":-11.715129,"twenty":-126.444312,"median":-28.295032,"eighty":80.255022,"marketCap":620316099},{"date":"2023-01-06","current":-11.346854,"twenty":-125.431062,"median":-25.10852,"eighty":80.129804,"marketCap":600815932},{"date":"2023-01-13","current":-13.541575,"twenty":-124.480726,"median":-21.758823,"eighty":79.936775,"marketCap":717026382},{"date":"2023-01-20","current":-13.257903,"twenty":-124.252248,"median":-20.468425,"eighty":79.81117,"marketCap":702005984},{"date":"2023-01-27","current":-12.939395,"twenty":-123.914499,"median":-20.219799,"eighty":79.508532,"marketCap":685140976},{"date":"2023-02-03","current":-14.084034,"twenty":-123.669464,"median":-19.981754,"eighty":79.275321,"marketCap":745749600},{"date":"2023-02-10","current":-13.1733,"twenty":-123.391317,"median":-19.773366,"eighty":78.392678,"marketCap":697526216},{"date":"2023-02-17","current":-12.939395,"twenty":-122.237123,"median":-19.352035,"eighty":78.237088,"marketCap":685140976},{"date":"2023-02-24","current":-12.123218,"twenty":-121.646854,"median":-19.194328,"eighty":78.044446,"marketCap":641924391},{"date":"2023-03-03","current":-9.769225,"twenty":-121.623097,"median":-18.990416,"eighty":77.996285,"marketCap":655886202},{"date":"2023-03-10","current":-7.706921,"twenty":-121.507203,"median":-18.763163,"eighty":77.67537,"marketCap":517427243},{"date":"2023-03-17","current":-8.470884,"twenty":-121.490646,"median":-18.651096,"eighty":77.514678,"marketCap":568718182},{"date":"2023-03-24","current":-8.910261,"twenty":-121.407864,"median":-18.327158,"eighty":77.346115,"marketCap":598217116},{"date":"2023-03-31","current":-8.993387,"twenty":-120.530377,"median":-18.243867,"eighty":76.98491,"marketCap":603797995},{"date":"2023-04-06","current":-8.827136,"twenty":-120.25223,"median":-18.109752,"eighty":76.792267,"marketCap":592636236},{"date":"2023-04-14","current":-9.233586,"twenty":-119.573419,"median":-17.654644,"eighty":76.705578,"marketCap":619924514},{"date":"2023-04-21","current":-9.5476,"twenty":-119.262158,"median":-17.35912,"eighty":76.599624,"marketCap":641006751},{"date":"2023-04-28","current":-8.804302,"twenty":-119.063482,"median":-17.187715,"eighty":76.440694,"marketCap":591103228},{"date":"2023-05-05","current":-8.18984,"twenty":-118.984012,"median":-16.797623,"eighty":75.90611,"marketCap":587367135},{"date":"2023-05-12","current":-8.442866,"twenty":-118.921097,"median":-16.759205,"eighty":75.624254,"marketCap":605513871},{"date":"2023-05-19","current":-8.747984,"twenty":-118.854872,"median":-16.543472,"eighty":75.272328,"marketCap":627396699},{"date":"2023-05-26","current":-9.369385,"twenty":-118.099901,"median":-16.162244,"eighty":74.854441,"marketCap":671962947},{"date":"2023-06-02","current":-7.832628,"twenty":-117.894602,"median":-15.796084,"eighty":74.668379,"marketCap":561748214},{"date":"2023-06-09","current":-5.33214,"twenty":-117.642945,"median":-15.68645,"eighty":74.514265,"marketCap":382415768},{"date":"2023-06-16","current":-4.986091,"twenty":-117.464137,"median":-15.580163,"eighty":74.456472,"marketCap":357597438},{"date":"2023-06-23","current":-4.930276,"twenty":-117.424402,"median":-15.417523,"eighty":74.456472,"marketCap":353594482},{"date":"2023-06-30","current":-4.933997,"twenty":-117.219102,"median":-15.257939,"eighty":74.432392,"marketCap":353861345},{"date":"2023-07-07","current":-4.941439,"twenty":-116.556848,"median":-15.108846,"eighty":74.33607,"marketCap":354395073},{"date":"2023-07-14","current":-6.02796,"twenty":-116.507179,"median":-14.859223,"eighty":74.263829,"marketCap":432319291},{"date":"2023-07-21","current":-6.214009,"twenty":-115.646247,"median":-14.557546,"eighty":74.167508,"marketCap":445662479},{"date":"2023-07-28","current":-5.894006,"twenty":-115.613135,"median":-14.258542,"eighty":74.167508,"marketCap":422712195},{"date":"2023-08-04","current":-5.663815,"twenty":-115.513796,"median":-14.240825,"eighty":73.926704,"marketCap":503218594},{"date":"2023-08-11","current":-5.280594,"twenty":-114.553527,"median":-14.178591,"eighty":73.01165,"marketCap":469170240},{"date":"2023-08-18","current":-5.208175,"twenty":-113.907828,"median":-14.052198,"eighty":72.867168,"marketCap":462735905},{"date":"2023-08-25","current":-5.64571,"twenty":-113.791934,"median":-13.89557,"eighty":72.843088,"marketCap":501610010},{"date":"2023-09-01","current":-6.013843,"twenty":-113.659483,"median":-13.834522,"eighty":72.3374,"marketCap":534317879},{"date":"2023-09-08","current":-5.66985,"twenty":-113.552925,"median":-13.793063,"eighty":72.260343,"marketCap":503754789},{"date":"2023-09-15","current":-5.310769,"twenty":-113.447412,"median":-13.581503,"eighty":72.241079,"marketCap":471851212},{"date":"2023-09-22","current":-5.027126,"twenty":-113.123056,"median":-13.47439,"eighty":72.241079,"marketCap":446650068},{"date":"2023-09-29","current":-5.247402,"twenty":-111.576691,"median":-13.437064,"eighty":72.20255,"marketCap":466221169},{"date":"2023-10-06","current":-4.483979,"twenty":-111.103179,"median":-13.330065,"eighty":72.115861,"marketCap":398392558},{"date":"2023-10-13","current":-3.678311,"twenty":-110.692581,"median":-13.257903,"eighty":72.096597,"marketCap":326810584},{"date":"2023-10-20","current":-3.862378,"twenty":-109.828339,"median":-13.190718,"eighty":72.058068,"marketCap":343164518},{"date":"2023-10-27","current":-3.946867,"twenty":-109.228998,"median":-13.161054,"eighty":72.033988,"marketCap":350671242},{"date":"2023-11-03","current":-5.912031,"twenty":-107.583295,"median":-13.139027,"eighty":71.942483,"marketCap":446381971},{"date":"2023-11-10","current":-6.105341,"twenty":-107.470712,"median":-13.073766,"eighty":71.720944,"marketCap":460977687},{"date":"2023-11-17","current":-6.860935,"twenty":-106.821702,"median":-13.014907,"eighty":71.306761,"marketCap":518028049},{"date":"2023-11-24","current":-7.085475,"twenty":-104.967388,"median":-12.997175,"eighty":71.037061,"marketCap":534981694},{"date":"2023-12-01","current":-7.12468,"twenty":-104.801825,"median":-12.950279,"eighty":70.892579,"marketCap":537941854},{"date":"2023-12-08","current":-6.878756,"twenty":-104.621466,"median":-12.939395,"eighty":70.868499,"marketCap":519373576},{"date":"2023-12-15","current":-7.345656,"twenty":-102.303773,"median":-12.93329,"eighty":70.844418,"marketCap":554626394},{"date":"2023-12-22","current":-7.766222,"twenty":-101.653193,"median":-12.899374,"eighty":70.675856,"marketCap":586380840},{"date":"2023-12-29","current":-7.994326,"twenty":-101.138387,"median":-12.831107,"eighty":70.661407,"marketCap":603603591},{"date":"2024-01-05","current":-7.242296,"twenty":-100.480612,"median":-12.765211,"eighty":70.642143,"marketCap":546822335},{"date":"2024-01-12","current":-7.345656,"twenty":-99.17597,"median":-12.686153,"eighty":70.492844,"marketCap":554626394},{"date":"2024-01-19","current":-6.957166,"twenty":-98.990539,"median":-12.535401,"eighty":70.049766,"marketCap":525293896},{"date":"2024-01-26","current":-7.356348,"twenty":-98.377953,"median":-12.367076,"eighty":69.495918,"marketCap":555433710},{"date":"2024-02-02","current":-8.439841,"twenty":-98.245502,"median":-12.314821,"eighty":69.375516,"marketCap":637241776},{"date":"2024-02-09","current":-8.500431,"twenty":-97.897818,"median":-12.148101,"eighty":69.255114,"marketCap":641816569},{"date":"2024-02-16","current":-8.867536,"twenty":-97.587065,"median":-12.126962,"eighty":69.014311,"marketCap":669534434},{"date":"2024-02-23","current":-8.682202,"twenty":-97.554536,"median":-12.050186,"eighty":68.879461,"marketCap":655540949},{"date":"2024-03-01","current":-8.626783,"twenty":-97.496408,"median":-11.968941,"eighty":68.556784,"marketCap":495746692},{"date":"2024-03-08","current":-9.911724,"twenty":-97.444174,"median":-11.921994,"eighty":68.446014,"marketCap":569587147},{"date":"2024-03-15","current":-9.219098,"twenty":-97.381259,"median":-11.8495,"eighty":67.954775,"marketCap":529784671},{"date":"2024-03-22","current":-10.07891,"twenty":-97.328279,"median":-11.779827,"eighty":66.774837,"marketCap":579194641},{"date":"2024-03-28","current":-10.164891,"twenty":-96.980595,"median":-11.747478,"eighty":66.394368,"marketCap":584135638},{"date":"2024-04-05","current":-10.145784,"twenty":-96.034573,"median":-11.715129,"eighty":65.869416,"marketCap":583037638},{"date":"2024-04-12","current":-9.975623,"twenty":-95.509954,"median":-11.674233,"eighty":65.541923,"marketCap":573259148},{"date":"2024-04-19","current":-9.21713,"twenty":-93.841259,"median":-11.590712,"eighty":65.486538,"marketCap":529671590},{"date":"2024-04-26","current":-9.365948,"twenty":-92.601993,"median":-11.540343,"eighty":65.296304,"marketCap":538223579},{"date":"2024-05-03","current":-20.460076,"twenty":-92.472226,"median":-11.516062,"eighty":65.156637,"marketCap":630088496},{"date":"2024-05-10","current":-21.891395,"twenty":-91.785206,"median":-11.553387,"eighty":65.07958,"marketCap":674167408},{"date":"2024-05-17","current":-21.712105,"twenty":-90.954077,"median":-11.630526,"eighty":64.939914,"marketCap":668645972},{"date":"2024-05-24","current":-21.281807,"twenty":-90.477253,"median":-11.705647,"eighty":64.858041,"marketCap":655394524},{"date":"2024-05-31","current":-21.70314,"twenty":-90.243501,"median":-11.725082,"eighty":64.752087,"marketCap":668369900},{"date":"2024-06-07","current":-20.645325,"twenty":-89.767451,"median":-11.754943,"eighty":64.597973,"marketCap":635793424},{"date":"2024-06-14","current":-20.331566,"twenty":-89.137652,"median":-11.784803,"eighty":64.569077,"marketCap":626130910},{"date":"2024-06-21","current":-18.888276,"twenty":-88.682246,"median":-11.8495,"eighty":64.511283,"marketCap":581683345},{"date":"2024-06-28","current":-18.968957,"twenty":-88.19431,"median":-11.87936,"eighty":63.91409,"marketCap":584167992},{"date":"2024-07-05","current":-19.049638,"twenty":-87.429878,"median":-11.962718,"eighty":62.979772,"marketCap":586652638},{"date":"2024-07-12","current":-16.575426,"twenty":-87.283498,"median":-11.973917,"eighty":62.661912,"marketCap":510456813},{"date":"2024-07-15","current":-16.629213,"twenty":-87.267233,"median":-11.978894,"eighty":62.498165,"marketCap":512113244},{"date":"2024-08-02","current":-20.654289,"twenty":-86.610826,"median":-11.921994,"eighty":63.018301,"marketCap":636069496},{"date":"2024-08-09","current":-249.174378,"twenty":-87.299762,"median":-11.921994,"eighty":63.018301,"marketCap":772191398},{"date":"2024-08-16","current":-242.909218,"twenty":-92.450772,"median":-11.921994,"eighty":63.018301,"marketCap":752775666},{"date":"2024-08-23","current":-246.399807,"twenty":-97.318345,"median":-11.921994,"eighty":63.018301,"marketCap":763593002},{"date":"2024-08-30","current":-266.627325,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":826278080},{"date":"2024-09-06","current":-263.852754,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":817679684},{"date":"2024-09-13","current":-274.593029,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":850963796},{"date":"2024-09-20","current":-273.250494,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":846803282},{"date":"2024-09-27","current":-250.606415,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":776629280},{"date":"2024-10-04","current":-254.365511,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":788278719},{"date":"2024-10-11","current":-253.291484,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":784950308},{"date":"2024-10-18","current":-295.894574,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":916977285},{"date":"2024-10-25","current":-284.617286,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":882028968},{"date":"2024-10-31","current":-309.140913,"twenty":-97.368014,"median":-11.921994,"eighty":63.018301,"marketCap":958027690},{"date":"2024-11-08","current":153.567604,"twenty":-91.563351,"median":-11.784803,"eighty":64.853225,"marketCap":932923196},{"date":"2024-11-15","current":142.134171,"twenty":-90.404405,"median":-11.754943,"eighty":65.240919,"marketCap":863465089},{"date":"2024-11-22","current":133.144173,"twenty":-90.404405,"median":-11.754943,"eighty":65.474498,"marketCap":808850852},{"date":"2024-11-29","current":139.598531,"twenty":-90.404405,"median":-11.754943,"eighty":66.977112,"marketCap":848061074},{"date":"2024-12-06","current":148.265811,"twenty":-90.404405,"median":-11.754943,"eighty":69.332172,"marketCap":900714800},{"date":"2024-12-13","current":134.250635,"twenty":-90.404405,"median":-11.754943,"eighty":70.85405,"marketCap":815572605},{"date":"2024-12-20","current":124.891816,"twenty":-90.404405,"median":-11.754943,"eighty":71.990643,"marketCap":758717784},{"date":"2024-12-27","current":124.937919,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":758997857},{"date":"2025-01-03","current":129.271559,"twenty":-90.404405,"median":-11.754943,"eighty":72.115861,"marketCap":785324720},{"date":"2025-01-10","current":150.847554,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":916398888},{"date":"2025-01-17","current":115.671306,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":702703182},{"date":"2025-01-24","current":122.171766,"twenty":-90.477253,"median":-11.764897,"eighty":72.096597,"marketCap":742193476},{"date":"2025-01-31","current":130.101405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":790366034},{"date":"2025-02-07","current":128.303405,"twenty":-90.477253,"median":-11.764897,"eighty":72.481883,"marketCap":779443186},{"date":"2025-02-14","current":127.289149,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":773281580},{"date":"2025-02-21","current":120.558176,"twenty":-90.477253,"median":-11.764897,"eighty":74.283094,"marketCap":732390921},{"date":"2025-02-28","current":38.806499,"twenty":-90.477253,"median":-11.764897,"eighty":76.356928,"marketCap":708024569},{"date":"2025-03-07","current":32.178981,"twenty":-90.550101,"median":-11.77485,"eighty":73.454249,"marketCap":587105504},{"date":"2025-03-14","current":29.318974,"twenty":-90.550101,"median":-11.77485,"eighty":33.288601,"marketCap":534924684},{"date":"2025-03-21","current":31.366301,"twenty":-90.550101,"median":-11.77485,"eighty":31.49758,"marketCap":572278167},{"date":"2025-03-28","current":31.413187,"twenty":-90.550101,"median":-11.77485,"eighty":31.375678,"marketCap":573133590},{"date":"2025-04-04","current":29.990998,"twenty":-90.550101,"median":-11.77485,"eighty":31.063109,"marketCap":547185751},{"date":"2025-04-11","current":30.162911,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":550322303},{"date":"2025-04-17","current":33.226087,"twenty":-90.477253,"median":-11.764897,"eighty":30.312944,"marketCap":606209957},{"date":"2025-04-25","current":33.089862,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":603724531},{"date":"2025-05-02","current":30.528678,"twenty":-90.550101,"median":-11.77485,"eighty":30.156659,"marketCap":556995733},{"date":"2025-05-09","current":-98.025753,"twenty":-95.154431,"median":-11.87936,"eighty":29.478384,"marketCap":496892541},{"date":"2025-05-16","current":-93.867775,"twenty":-96.90247,"median":-11.978894,"eighty":-3.786337,"marketCap":475815751},{"date":"2025-05-23","current":-90.507217,"twenty":-96.90247,"median":-12.148101,"eighty":-3.979456,"marketCap":458781085},{"date":"2025-05-30","current":-90.848969,"twenty":-96.90247,"median":-12.322286,"eighty":-4.309569,"marketCap":460513424},{"date":"2025-06-06","current":-96.943539,"twenty":-96.977714,"median":-12.588852,"eighty":-4.550363,"marketCap":491406801},{"date":"2025-06-13","current":-107.196088,"twenty":-97.40775,"median":-12.795071,"eighty":-4.74909,"marketCap":543376968},{"date":"2025-06-17","current":-109.759225,"twenty":-97.732254,"median":-12.899374,"eighty":-4.847918,"marketCap":556369510}],"updateTime":1750241018731}}}